

Continuing Education Program

Addiction at the Crossroads of Mental and Physical Health

Fifth Annual Meeting
March 24-25, 2017
Albuquerque, NM



COLLABORATIVE
PERSPECTIVES on
ADDICTION

CONTINUING EDUCATION

Continuing Education will be offered for some programming at the Collaborative Perspectives on Addiction meeting (CPA). Please note, clinical mini-workshops are included in the cost of the conference. To receive CE credits for attending the clinical mini-workshops, attendees must also pay the \$35 CE fee for CE processing—see #1 below.



Those programs being offered for continuing education credit are noted on the printed conference program with the CE designation shown on the left.

A PDF downloadable file will be placed on the website prior to the conference with the above information. There is an additional fee associated with CE processing and it is reflected in the registration form, the final printed program as well as on the conference website.

Information about the CE on the conference website and final printed program will include a description of the educational objectives for each eligible program; the intended audience and instructional level of the program; instructor background, credentials and level of expertise; the day and time of the program; fees; and the number of CE credits offered for each program. Where applicable, information about commercial support or potential conflict of interests will also be clearly indicated.

Continuing education for programming is being co-sponsored by APA Division 50. **The Society for Addiction Psychology, APA Division 50, is approved by the American Psychological Association to sponsor continuing education for psychologists. APA Division 50 maintains responsibility for this program and its content.**

Any questions regarding CE offerings should be directed to CE Chair Cynthia Glidden-Tracey, PhD via email at Cynthia.Glidden-Tracey@asu.edu. You may also contact Katie Witkiewitz, PhD, 2017 CPA Lead Coordinator at katiw@unm.edu or at 505-277-5953 (Office). If any concerns arise during the conference about any CE activity, please read the grievance procedures that have been established by the CE committee (see inside back cover of this booklet).

How to Receive Continuing Education Credit

In order to be eligible to receive Continuing Education credit for any/each eligible program (that is, CPA events with the CE designation), participants MUST comply with ALL of the following:

1. Register and pay for CE processing via the CPA registration form.
2. Sign-in at the beginning of the offering/program/event on a sign-in sheet that will be located at the entrance of every room where a CE program is being offered.
3. Sign-out at the end of the offering/program/event on a sign-in sheet that will be located at the entrance of every room where a CE program is being offered.
4. Complete and submit each of the 4 electronic evaluation forms that will be emailed to each participant who registered for CE credits. The links for the evaluations will be emailed to participants in 4 separate emails, divided as follow: Morning Session Friday, March 24, Afternoon Session Friday, March 24; Morning Session Saturday March 25, Afternoon Session Saturday March 25.
5. Participants will have up to four weeks after the end of the conference to submit their responses, and they MUST respond to all 4 electronic evaluations. Responses must be received on or before Monday April 24, 2017.
6. CE certificates will be emailed to all participants who have complied with ALL the above instructions. Certificates will be received no later than May 22, 2017.
7. No certificates will be issued after May 22, 2017.

CONTINUING EDUCATION SESSIONS

Keynote Sessions (1 CE)

1. Motivational Interviewing at the Crossroads Approved for CE, content area 1.1

Abstract. Motivational interviewing (MI) evolved from the person-centered approach of Carl Rogers. With more than 500 published clinical trials, MI is an evidence-based psychotherapy for evoking and strengthening clients' own motivations for change. It was originally developed for treating alcohol problems, but ambivalence about change is human nature and is a significant clinical issue in health care and social services more generally. After briefly describing the method Dr. Miller will discuss how therapists develop and maintain fidelity in providing a complex clinical method like MI, with more general implications for hiring and continuing professional education of providers.

Presenter. William R. Miller, Ph.D.

Presenter Qualifications. Dr. William R. Miller is Emeritus Distinguished Professor of Psychology and Psychiatry at the University of New Mexico where he served as Director of Clinical Training for the doctoral program in clinical psychology and as Co-Director of the Center on Alcoholism, Substance Abuse and Addictions (CASAA). Dr. Miller's publications include over 50 books and 400 articles and chapters including the original 1983 description of the clinical method of motivational interviewing. Fundamentally interested in the psychology of change, he has focused in particular on the development, testing, and dissemination of behavioral treatments for addictions. With more than 40 years of experience in addiction research and treatment, he has served as principal investigator for numerous research grants and contracts, founded a private practice group, directed a large public treatment program, and served as a consultant to many organizations including the United States Senate, the World Health Organization, the National Academy of Sciences, and the National Institutes of Health. In recognition of his research contributions, Dr. Miller is a recipient of the international Jellinek Memorial Award, two career achievement awards from the American Psychological Association, and an Innovators in Combating Substance Abuse award from the Robert Wood Johnson Foundation. He maintains an active interest in the interface of spirituality and psychology. His books have been translated into 26 languages and the Institute for Scientific Information has listed him as one of the world's most cited scientists.

Learning Objectives. Following this presentation, participants will be able to:

1. Contrast the four component processes of motivational interviewing with the "righting reflex" to persuade
2. Provide several examples of client "change talk" and "sustain talk"

3. Name two training enrichments that are effective for developing competence in motivational interviewing

2. Brain Imaging, Temperament and Cognitive Function in a Monkey Model or Chronic Alcohol Self-Administration Approved for CE, content area 1.3

Abstract. The macaque monkey model of voluntary alcohol self-administration has provided translational data addressing risk factors and consequences of chronic alcohol drinking. Recent advances include antecedent resting state MRI amygdalar-cortical connectivity, aggressive and anxious temperaments and cognitive flexibility as measured in set-shifting tasks. Each of these highly translational datasets can help identify and isolate variables in human subject studies to better address prevention and treatment approaches in alcohol use disorders.

Presenter. Kathleen A. Grant, Ph.D.

Presenter Qualifications. Dr. Kathleen A. Grant is a Professor, and Chief of the Division of Neuroscience at the Oregon National Primate Research Center (ONPRC). She is also a Professor in the Department of Behavioral Neurosciences at OHSU. She earned her Ph.D. in Psychology from the University of Washington in 1984. This was followed by a 3-year postdoctoral fellowship at the University of Chicago. In 1987, she took an appointment as Staff Fellow at the National Institute on Alcohol Abuse and Alcoholism, becoming a Senior Staff Fellow in 1990. In 1991, she joined the faculty at Wake Forest University School of Medicine, where she remained until her appointment to the Primate Center and OHSU in 2005. Research in the Grant laboratory uses two fundamental paradigms in behavioral pharmacology to understand the risk for and consequences of heavy ethanol consumption: drug discrimination and self-administration. The consequences of heavy ethanol consumption are investigated with changes in functional genomics and proteomics, in vivo imaging with MRI/MRS, and endocrinological status. Along with this longitudinal approach, the lab has identified a combination of soluble proteins that serve as a sensitive marker for any alcohol use, as well as excessive alcohol use. These biomarkers can aid in clinical practice, helping to identify harmful drinking levels and adherence to abstinence programs.

Learning Objectives. Following this presentation, participants will be able to:

1. Describe approaches to measuring face, construct and predictive validity of the non human primate model to human subject research on excessive drinking phenotypes
2. Understand and characterize species translational measures of resting state function connectivity MRI
3. Contrast a new paradigm for assessing cognitive function in monkeys with existing paradigms

Clinical Workshop Sessions

1. Emotion Regulation Training (ERT) for Alcohol Use Disorders: Helping Clients Manage Negative Emotions

Abstract. The combination of negative affect and difficulties regulating negative affect has implications for the development, maintenance and treatment of alcohol use problems. This introductory mini-workshop on how to implement Emotion Regulation Training (ERT) for individuals with an alcohol use disorder will begin by presenting the conceptual underpinnings of the ERT intervention, describe its basic components, and provide illustrative case vignettes. Participants will receive instruction on how to identify a set of negative affect drinking situations. The remainder of the workshop will provide a step-by-step guide on how to implement a core therapeutic principle of ERT—learning to manage negative emotions and cravings.

Presenters. Clara M. Bradizza, Ph.D., Kim Slosman, M.S., & Paul R. Stasiewicz, Ph.D.

Continuing Education: 2 hours

Learning Objectives. Following this presentation, participants will be able to:

1. Describe the theoretical rationale for the Emotion Regulation Treatment and be able to explain it to clients
2. Identify and develop a set of high-risk negative affect drinking situations
3. Implement the ERT strategies of mindfulness and prolonged direct experiencing of emotion to help clients to more effectively manage negative affect without drinking

2. Cognitive-Behavioral Therapy (CBT) for Alcohol and Drug Problems

Abstract. Cognitive behavior therapy (CBT) for alcohol and drug problems is a well-established treatment with a strong evidence base. The goal of this workshop is to provide clinicians-in-training and practitioners with training in other treatment approaches with an overview of the CBT approach and basic skills in conducting a functional analysis, using selected assessment approaches such as behavioral self-recording, and teaching clients basic abstinence-focused skills. The workshop will use active learning techniques including group exercises, role-play illustrations, and application of workshop material to sample cases.

Presenter. Barbara S. McCrady, Ph.D.

Continuing Education: 2.75 hours

Learning Objectives. Following this presentation, participants will be able to:

1. Describe the CBT model for conceptualizing alcohol and drug use
2. Apply functional analysis to case conceptualization and treatment planning
3. Describe CBT intervention strategies to attain and maintain change in alcohol or drug use

3. Treating Suicidal Thoughts and Behaviors in Adults with Substance Use Disorders (SUDs)

Abstract. Individuals with substance use disorders (SUDs) are at clear elevated risk for suicide. Our research group is in the process of testing the efficacy of an evidence-based intervention for suicide risk reduction with individuals in SUD treatment. This workshop will review the cognitive-behavioral model for suicidal thoughts and behaviors. We will provide descriptions of techniques and strategies to specifically target suicidal thoughts and behaviors among those with SUDs, as well as detailed case examples. The workshop is intended for SUD clinicians, administrators and researchers who are interested in improving skills for directly targeting suicide risk during SUD treatment.

Presenters. Mark Ilgen, Ph.D. and Erin Goldman, L.M.S.W.

Continuing Education: 1.25 hours

Learning Objectives. Following this presentation, participants will be able to:

1. Understand the clinical rationale and effectiveness of targeting suicide as the primary focus of treatment
2. Understand the cognitive-behavioral model of suicidal thoughts and behaviors in those with substance use disorders
3. Identify CBT techniques and strategies for addressing dysfunctional thinking associated with suicidal ideation and behavior among those receiving substance use disorder treatment

4. SBIRT Basics: Development and Application of SBIRT Skills in Diverse Settings

Abstract. This workshop will present cutting-edge research and training on integrating the evidence-based practice of screening, brief intervention, and referral to treatment (SBIRT) for alcohol and other drugs in primary health and mental health care settings. Participants will learn the practical implications of using SBIRT as well as challenges to implementing this intervention in the workplace. The workshop will deliver the foundational knowledge and skills related to motivational interviewing (MI) and conducting SBIRT in various clinical settings, as well as ample opportunity for participants to practice and gain feedback on MI and SBIRT skills.

Presenters. Jessica L. Martin, Ph.D., M. Dolores Cimini, Ph.D., & Laura M. Longo, M.S.

Continuing Education: 2.75 hours

Learning Objectives. Following this presentation, participants will be able to:

1. Describe the research supporting the efficacy of Screening, Brief Intervention, and Referral to Treatment (SBIRT) within behavioral health care settings and other service delivery environment.
2. Select the most appropriate screening tools and methods for assessing alcohol and drug use for different target populations across the life span identified in the literature as being at risk for use and related consequences.

- Utilize motivational interviewing techniques to deliver target population-relevant and responsive brief interventions addressing alcohol and drug use.

5. Drug Use, Misuse, and Abuse: Recent Advances in Psychopharmacology

Abstract. The purpose of this mini-workshop is to provide a general audience with an overview of how recreational drugs affect the brain and behavior and can lead to addiction. Converging evidence from a variety of different disciplines will be presented to demonstrate how the use of legal and illegal drugs influences brain functioning. The biological basis of drug action in the brain for the major drugs of abuse (alcohol, nicotine, caffeine, marijuana, heroin, methamphetamine, cocaine, LSD, ecstasy, etc.) will be covered as part of this workshop. Findings from both human and animal research will be highlighted including recent advances in imaging the living brain. In addition, the current medications being used to effectively treat addiction will be highlighted.

Presenter. Cecile A. Marczyński, Ph.D.

Continuing Education: 3 hours

Learning Objectives. Following this presentation, participants will be able to:

- Develop knowledge about the field of psychopharmacology including a better understanding of how physiological and psychological factors contribute to drug use and addiction.
- Develop critical thinking skills in regard to how recent advances in scientific research about addiction changes how addiction should be approached and treated.
- Identify the variety of risk and protective factors (e.g., biological, sociocultural, etc.) that increase or decrease the likelihood of addiction to legal and illegal drugs.

Symposium Sessions (1.25 CEs)

1. Obesity and Substance Use: A Complex Relationship

Abstract. Excessive substance use and elevated body mass index (BMI) are leading causes of preventable death. Obesity and substance use disorders are associated with many of the same factors, including reward dysfunction. Dr. Sonja Yokum will present research on how patterns of reward processing in the brain similarly predict the onset of future substance use and excessive weight gain during adolescence. However, the food-drug competition hypothesis proposes that because food and drugs of abuse engage similar reward-related neural circuitry, they may compete for shared brain reward sites. Thus, excess consumption of food may diminish desire for drugs of abuse (and vice versa) by occupying shared brain reward sites. In support of this hypothesis, Dr. Ashley Gearhardt will discuss research on how elevated BMI across adolescence is protective against problematic substance use in young adulthood and Ms. Jenna Cummings will present on how motivations to consume alcohol and sweet high-fat food compete within adults. A greater understanding of the complex relationship between obesity and substance use is needed to inform intervention efforts to reduce

the impact of these conditions on public health.

Presenters. Ashley Gearhardt, Ph.D.; Sonja Yokum, Ph.D.; Jenna R. Cummings, M.A.

Presenter Qualifications. Ashley Gearhardt, Ph.D. is an Assistant Professor of Psychology at the University of Michigan. Dr. Gearhardt is a pioneer in examining the role of addictive mechanisms in eating behavior using multi-method approaches (e.g., neuroimaging, scale development, behavioral phenotyping). She is the author of the Yale Food Addiction Scale, which is a psychometrically sound measure to assess addictive-like eating behavior. She has published over 45 peer-reviewed journal articles and is currently the Primary Investigator on a NIH-funded R01 grant to investigate neural susceptibility to food advertising in adolescents. Sonja Yokum, Ph.D. is a Research Scientist at Oregon Research Institute. Dr. Yokum's program of research focuses on the understanding of neural and biological risk- and maintenance factors for obesity, eating disorders, and substance use. To this end, she uses a multi-method approach to explore the role of genetic, neurological, and behavioral factors in eating pathology and substance use. She has conducted three NIH-funded large-scale prospective fMRI studies on risk factors that predict future body mass, disordered eating behaviors and substance use and has examined neural plasticity of reward regions that occurs secondary to overeating. Jenna R. Cummings, M.A., is a Doctoral Student in Health Psychology at the University of California, Los Angeles. Jenna's program of research crosses work on eating and drinking behavior while exploring topics like reinforcement, addiction, genetics, social relationships, and stress. Her research is funded by the Association for Psychological Science, the UCLA Institute for Society and Genetics, and a National Science Foundation Graduate Research Fellowship.

Learning Objectives. Following this presentation, participants will be able to:

- Investigate how elevated activation in brain reward regions predict future onset of substance use and initial excessive body fat gain.
- Examine how BMI trajectories across adolescence predict substance use problems in young adulthood.
- Describe how motivations to consume alcohol consumption and sweet high-fat foods compete within individuals during adulthood.

2. Emotion Dysregulation in Substance Use and Substance Use Disorders

Abstract. Although the link between emotion and substance use is broadly recognized, investigations continue to provide significant insight to the relationships between various affect-related domains and drug/alcohol use, misuse, and dependence. This session explores a broad range of affect-related factors and their dysregulation in the context of substance use. Dr. Leventhal will apply a transdiagnostic emotional vulnerability model to understanding comorbidity between emotional psychopathology and alcohol, tobacco, and marijuana use in adolescents. He will demonstrate associations between diagnostic vulnerability factors common to several psychological disorders (e.g., negative urgency & anxiety sensitivity) and increased likelihood of substance use. Ms. Hoffman will discuss neurobehavioral correlates of emotional processing in alcohol

dependent treatment seekers. Neurophysiological and behavioral data will speak to alcohol-related dysfunction in processing/identifying the outward emotional expressions of others and how they relate to interpersonal difficulties. Dr. Witkiewitz will describe the role of negative affect as a mediator of alcohol relapse in clinical trial participants. Moderators of these negative affect and relapse associations will also be addressed. Discussion, led by Dr. Nixon, will emphasize the role of emotion dysregulation in substance use and explore potential implications for research, prevention, and treatment.

Presenters. Lauren A. Hoffman, MS; Katie Witkiewitz, PhD; Adam Leventhal, PhD; Sara Jo Nixon, PhD

Presenter Qualifications. Lauren Hoffman is a Ph.D. candidate in the Behavioral and Cognitive Neuroscience program within the University of Florida's Psychology Department. She received her Master of Science degree in 2013 and anticipates receipt of her doctoral degree in 2017. Ms. Hoffman's academic focus is the study of substance use, misuse, and dependence, with her dissertation research specifically addressing neurobehavioral indices of affective stimulus processing and interpersonal functioning in alcohol dependent treatment seekers. Dr. Katie Witkiewitz graduated from the University of Washington Clinical Psychology PhD program in 2005. She is currently an Associate Professor of Psychology at the University of New Mexico and the President of the Society of Addiction Psychology. As a licensed clinical psychologist, Dr. Witkiewitz's research focuses on the development and evaluation of mindfulness based interventions for alcohol and drug use disorders, as well as gaining a better understanding of the addiction relapse process. Adam Leventhal, Ph.D., Associate Professor of Preventive Medicine and Psychology at the University of Southern California Keck School of Medicine and USC Norris Comprehensive Cancer Center, is an addiction psychologist with expertise in the epidemiology and psychopharmacology of tobacco use and other addictive or health-damaging behaviors. He is Director of the USC Health, Emotion, & Addiction Laboratory, which conducts interdisciplinary research on the intersection between addiction, mental health, and health behavior. Dr. Sara Jo Nixon currently holds several positions at the University of Florida, including Co-Director of the Center for Addiction Research and Education, Chief of the Division of Addiction Research, Co-Vice Chair of Research, and Professor in the Department of Psychiatry. She is an established researcher in the field of addiction psychology whose clinical research concerns the behavioral, psychosocial, and neurobiological concomitants of substance use and dependence. She is an APA fellow, former President of Division 50, and currently serves on APA's Board of Scientific Affairs and the University of Florida's Institutional Review Board.

Learning Objectives. Following this presentation, participants will be able to:

1. Discuss the association between mood disorders (e.g., depression, anxiety) and substance use disorders from a transdiagnostic vulnerability perspective that considers vulnerability factors common to several psychological disorders.
2. Describe alcohol-related neurobehavioral concomitants of emotional processing, including three behavioral (performance) and two neurophysiological correlates, and their relationship to interpersonal problems.

3. Rate the importance of negative affect in the prediction of alcohol relapse and describe moderators of negative affect-alcohol relapse associations.

3. Comorbid Substance Use and Mental Health Conditions: Implications for Prevention and Treatment

Abstract. This symposium will take a lifespan approach to addiction and co-occurring psychopathology, underscoring factors that affect development, maintenance, screening, and treatment of these conditions. Dr. Brenna Greenfield will discuss developmental trajectories of alcohol use disorder (AUD) and conduct disorder symptoms among Indigenous youth ages 10-18, including predictors and associated outcomes of these trajectories. Dr. Justin Anker will discuss factors that maintain co-occurring AUDs and internalizing conditions (e.g., anxiety, depression). Using a network analysis of AUD and internalizing conditions with 363 adults entering AUD treatment, he will show that co-occurring disorders are likely maintained through stress and drinking to cope. Dr. Kevin Hallgren will present data indicating a 10-fold increase in risk for ideating or attempting suicide among non-treatment-seeking drug users in primary care clinics, followed by a discussion of implications for screening and treatment of these conditions within primary care. Corey Roos will present data from a clinical trial evaluating the efficacy of mindfulness-based relapse prevention (MBRP) among 286 individuals with substance use disorders. He will show that MBRP may have the strongest effect in reducing substance use for individuals with the highest levels of co-occurring psychopathology, suggesting that MBRP may be a promising "transdiagnostic" treatment. Dr. Sarah Bowen will discuss overarching clinical and research implications.

Presenters. Brenna Greenfield, PhD, Kevin Hallgren, PhD, Justin Anker, PhD, Corey Roos, MS, and Sarah Bowen PhD

Presenter Qualifications. Brenna Greenfield, PhD, is an Assistant Professor in the Department of Biobehavioral Health & Population Sciences at the University of Minnesota Medical School, Duluth campus. Her research focuses on developing and testing substance use disorder treatment for American Indians using community-based participatory research. Justin J. Anker, Ph.D. is an Assistant Professor in Psychiatry at the University of Minnesota. His research focuses on elucidating mechanisms by which psychological stress, anxiety, and pathological alcohol use interact among individuals with co-occurring anxiety and alcohol use disorders. Kevin A. Hallgren, Ph.D. is a licensed psychologist and acting assistant professor in Psychiatry and Behavioral Sciences at the University of Washington. His research focuses on treatment for alcohol and drug use disorders with a focus on modeling processes and mechanisms of behavior change and promoting effective service delivery. Corey Roos, M.S. is a 4th year graduate student in the Clinical Psychology doctoral program at the University of New Mexico. He is interested in treatment for addictive disorders, with a particular focus on the development and implementation of mindfulness-based treatments. Mr. Roos has published over 10 peer-reviewed papers related to the topic of the symposium. Sarah Bowen, PhD, is an Assistant Professor at Pacific University outside Portland, OR, and is a licensed clinical psychologist. Her research, which has included several NIH-funded grants and over 40 peer-reviewed journal articles and book chapters, focuses on the integration of behavioral and mindfulness-based approaches for treatment

of addictive behaviors. She has a specific interest in dual diagnosis and underserved populations.

Learning Objectives. Following this presentation, participants will be able to:

1. Describe trajectories of comorbid psychiatric symptoms during adolescence.
2. List three common psychiatric issues that commonly co-occur with addiction.
3. Identify two promising methods to screen and treat individuals with substance use disorders and comorbid psychopathology.

4. Addressing the Needs of Pregnant Women in Substance Use Treatment

Abstract. Prenatal substance use disorders (SUD) represent an ongoing problem with long-term consequences for affected mothers, children, and families. Approximately 5% of women entering treatment for an SUD in the U.S. are pregnant. Pregnant women with SUD often have trouble engaging in treatment, high rates of psychiatric comorbidity, and high relapse rates during pregnancy and postpartum. This symposium will cover topics from laboratory studies to treatment approaches, presenting both empirical research and clinical experience including neuroimaging and clinical trial data, population-specific assessment techniques, and advances in treatment strategies to address needs of these patients. Dr. Stephen will present data examining infant neurophysiological correlates of prenatal alcohol exposure and neonatal abstinence syndrome. Dr. Sanjuan will present two pilot studies 1) assessing daily PTSD symptoms and prenatal bonding in conjunction with episodes of substance use and 2) assessing prenatal bonding with EEG. Dr. Coffey will present a clinical trial of prolonged exposure therapy for PTSD for pregnant women in residential SUD treatment. Dr. Sutter will present data from a group prenatal care program for women on opioid maintenance therapy. Dr. Leeman, Medical Director of the UNM Milagro Program, as the discussant, will address unmet needs in the care of pregnant women with SUD.

Presenters. Pilar M. Sanjuan, Ph.D., Julia Stephen, Ph.D., Scott Coffey, Ph.D., Mary Beth Sutter, M.D., Lawrence Leeman, M.D., MPH

Presenter Qualifications. Julia Stephen, Ph.D. MEG Core Director, Associate Professor of Translational Neuroscience, The Mind Research Network. Dr. Stephen has served as the MEG/EEG Core Director at the Mind Research Network since 2009. Her recent research has harnessed the utility of using magnetoencephalography (MEG) for assessment of neuropathology in pediatric populations to examine the effects of prenatal alcohol and opiate exposure on brain development in children as young as 3 months of age. Pilar M. Sanjuan, Ph.D. Research Assistant Professor, Center on Alcoholism, Substance Abuse, and Addictions, University of New Mexico. Dr. Sanjuan has been conducting research on PTSD and SUD comorbidity since 2009. She has recently been funded to conduct preliminary research on the role of PTSD and SUD comorbidity on prenatal bonding and also to look at different ways to assess the role of prenatal bonding among women in treatment for SUD. Scott F. Coffey, Ph.D., Professor and Vice Chair for Research; Director,

Division of Psychology; Department of Psychiatry and Human Behavior; The University of Mississippi Medical Center. Dr. Coffey is an expert on PTSD and SUD comorbidity, conducting NIH funded research in this area for over 17 years. For the past 2 years he has been funded by SAMHSA to evaluate the impact of providing trauma-informed care to pregnant and postpartum addicted women. Mary Beth Sutter, M.D., Assistant Professor, Family and Community Medicine, University of New Mexico School of Medicine. Dr. Sutter is a medical provider in the Milagro Prenatal Substance Abuse Clinic, and cares for mothers and babies during pregnancy and treatment for neonatal withdrawal. Her recent research focuses on initiating group prenatal care for women of the Milagro clinic. Lawrence Leeman, M.D., MPH; Medical Director, Maternal Child and Health Program; Medical Director, Milagro Program; Medical Co-Director, UNM Hospital Mother-Baby Care Unit; Family and Community Medicine; University of New Mexico School of Medicine. Dr. Leeman is a Professor in Family Medicine and Ob/Gyn at the University of New Mexico. He is Medical Director of the Milagro perinatal substance abuse program as well as Co-Medical Director of the University Hospital Mother Baby Unit and Intermediate Care Nursery. His perinatal substance abuse related research has included the effect of methadone and buprenorphine on maternal and neonatal outcomes, barriers to breastfeeding in women with opioid use disorder, and the treatment of neonatal abstinence syndrome. He has helped transition the Milagro program to a medical home model where buprenorphine is now the most common form of Medication Assisted Treatment (MAT).

Learning Objectives. Following this presentation, participants will be able to:

1. Describe two of the effects of prenatal alcohol and opiate exposure on the developing fetal brain.
2. Explain one approach to assessing the relationship between comorbidity and substance use with pregnant women.
3. Describe one treatment approach that helps meet the needs of pregnant women in SUD treatment.

5. Emotion Regulation Difficulties as a Concomitant Substance Use Problem

Abstract. Emotion regulation difficulties are defined by the absence of adaptive strategies and the use of maladaptive strategies for regulating emotional responses. This symposium will discuss recent and novel findings demonstrating that emotion regulation difficulties may result in increased marijuana, tobacco, and alcohol use problems. Dr. Brown's work shows an indirect effect of coping motives on the association of emotion regulation difficulties (e.g. emotion nonacceptance) with marijuana use problems (e.g. "Did you ever use marijuana after you had decided not to?"). Dr. Fillo's investigation suggests that increased sleep disturbance is related to emotion dysregulation, which, in turn, contributes to more tobacco cessation-related problems, (e.g. low self-efficacy for abstinence). Dr. Bradizza will discuss the relationship between anxiety and mood disorder comorbidity among individuals with an alcohol use disorder and emotion regulation difficulties. This research suggests that a substance use disorder diagnosis alone is not a sufficient marker of ERD. Rather, individuals with AUD and multiple comorbidities report greater ERD, which may make them vulnerable to relapse.

Novel in this symposium is the identification of individual difference and mental health vulnerabilities that are associated with greater ERD beyond substance use disorder diagnoses. Poor emotion regulation is an important transdiagnostic treatment target for individuals with substance use disorders and other physical and mental health comorbidities.

Presenters. Whitney C. Brown, PhD; Jennifer Fillo, PhD; Clara Bradizza, PhD

Presenter Qualifications. Whitney C. Brown, Ph.D. is a Postdoctoral Fellow at the Research Institute on Addictions, University at Buffalo. Her research focuses on the relations among between emotion, substance use, and psychopathology using ecological momentary assessment and other daily methods. Clara M. Bradizza, Ph.D. is a Senior Research Scientist at the Research Institute on Addictions, University at Buffalo. Her research includes the understanding of the relationship of emotions and addiction, and the development emotion-focused interventions for alcohol use and tobacco use disorders. Jennifer Fillo, Ph.D. is a Postdoctoral Fellow at the Research Institute on Addictions, University at Buffalo. Her research focuses on responses to acute and chronic stress, including individual differences in emotion regulation tendencies and their implications for substance use and other health-related behavior.

Learning Objectives. Following this presentation, participants will be able to:

1. Discuss the impact that coping motives have on the complex relationship between emotion regulation difficulties and marijuana use problems.
2. Describe the impact of sleep problems on difficulties in emotion regulation and tobacco cessation.
3. Describe the relationship between psychiatric comorbidity, emotion regulation, and alcohol use disorder.

6. The “Future’s So Bright”? Recent Trends in Technology-Enhanced Addiction Recovery Management

Abstract. The innovation and increased reach offered by modern technologies may enhance self-management, facilitate recovery support, and supplement face-to-face treatment approaches for individuals with substance use disorder (SUD) and other harmful substance use. While computer-to-person web and text message-based tools confer benefit, comparatively less is known about several newer technologies, three of which are the focus of this symposium. First, we will present a content analysis of drinking-related smartphone “apps” available on Google Play ($n = 266$). Results showed that tracking-over-time features were particularly popular, both in terms of number of downloads and star ratings. Second, we present survey data characterizing participation and perceived benefit among members of a large, existing recovery-specific social network site ($N = 123$). Overall, members perceived similar participation-related benefits (e.g., enhanced abstinence/recovery motivation) irrespective of time in recovery. Third, we present an overview and demonstration of two studies that tested heart rate variability biofeedback (HRV BFB) with smartphone app practice tools as an adjunct to SUD treatment-as-usual in young adult clinical samples. Results showed HRV BFB may compliment treatment-as-usual by reducing craving and

negative affect. The discussant will highlight both the potential impact of these technologies in treatment and recovery, and their potential transdiagnostic implications (e.g., negative affect).

Presenters. Brandon Bergman, PhD, Bettina Hoepfner, PhD, David Eddie, PhD, and John Kelly, PhD

Presenter Qualifications. Dr. Bergman received his Ph.D. in clinical psychology from Nova Southeastern University, completed an addiction psychology fellowship at the Recovery Research Institute (RRI) and Addiction Recovery Management Service in the Department of Psychiatry at the Massachusetts General Hospital, and currently works as a research scientist at the RRI. His primary research interests include the intersection between online social network sites and addiction recovery, as well as treatment and recovery processes during the life stage of emerging adulthood. Bettina Hoepfner received her Ph.D. in experimental psychology and her master’s in statistics from the University of Rhode Island, and completed her postdoctoral training in addiction at the Center for Alcohol and Addiction Studies at Brown University. Since 2010, she has been a research faculty member in the psychiatry department of the Massachusetts General Hospital. Her line of research focuses on delineating mechanisms of change in addictive behavior change, both in terms of fine-grained processes (e.g., via ecological momentary assessment; via smartphone app interactions) and longer-term developments (e.g., multiple mediation modeling of longitudinal studies). Dr. Eddie received his B.A. from Columbia University, his Ph.D. in clinical psychology from Rutgers University, and completed his clinical residency at Massachusetts General Hospital, Harvard Medical School. His research focuses on the psychophysiological processes underpinning emotion regulation, and how deficits in such processes are implicated in the etiology and treatment of substance use disorders. Dr. Kelly is the Elizabeth R. Spallin Associate Professor of Psychiatry in the Field of Addiction Medicine at Harvard Medical School, as well as the founder and Director of the Recovery Research Institute and the Associated Director of the Center for Addiction Medicine at the Massachusetts General Hospital. His clinical and research work has focused on addiction treatment and the recovery process including the translation and implementation of evidence-based practices, addiction and criminal justice, addiction treatment theories and mechanisms of behavior change, and reducing stigma associated with addiction.

Learning Objectives. Following this presentation, participants will be able to:

1. Identify and describe features associated with popularity and user-rated quality in alcohol-related smartphone “apps”
2. Define “recovery-specific social network site” and describe members’ perceived benefits
3. Explain heart rate variability biofeedback and how it can be used to enhance addiction treatment-as-usual

7. Heart Rate Variability as a Dynamic, Real-Time Indicator of Active Brain and Behavior Mechanisms

Abstract. Alcohol and drug use behaviors are determined on a ‘moment-to-moment basis’, with each moment being driven by intentional-cognitive processes and physiological reactions that

occur outside of conscious awareness and proceed automatically (i.e., automatic-visceral reactions). Heart rate variability (HRV) is a commonly used measure of automatic-visceral reactions and HRV biofeedback is being used with increasing frequency in the clinical treatment world. This session focuses on how psychophysiology provides insight into both physical and mental health and may be a useful adjunctive intervention for many addictive and other maladaptive behaviors. The first presenter (M. Bates) will discuss the use of HRV to bolster against triggers for relapse during addiction treatment. The second (B. Fink) will discuss HRV as a potential index of emotion regulation in partners with a history of intimate partner violence. The third (T. Leyro) will discuss autonomic dysregulation as a physiological mechanism that may explain both attentional bias and emotion regulatory impairments that contribute to smoking maintenance, with specific relevance to anxious smokers. The final talk (J. Buckman) will discuss HRV as a lens for understanding the many integrated adaptive biological systems that contribute fundamentally to psychosocial risk and health outcomes through anatomically and chemically well-defined feedback loops.

Presenters. Jennifer Buckman, PhD; Marsha Bates, PhD; Brandi Fink, PhD; T. Leyro, PhD

Presenter Qualifications. Jennifer Buckman, PhD is an Associate Research Professor at the Center of Alcohol Studies, Rutgers University. Her current research focuses on biological functioning (particularly of the heart and vessels) in response to acute and chronic alcohol challenge and how these biological reactions impact behavioral change and emotional experience. Dr. Buckman was Treasurer of the Society of Addiction Psychology (2006 – 2015) and received a Distinguished Service Award and Presidential Special Award from the society in 2013. Marsha E. Bates, PhD is a Distinguished Research Professor of Psychology at the Center of Alcohol Studies (CAS) at Rutgers University. She directs the Cardiac Neuroscience Laboratory that promotes translation between human experimental and clinical science and studies alcohol effects on memory, cognition, arousal regulation, and neurocardiac signaling. Dr. Bates is a Fellow of the APA, past President of the Society of Addiction Psychology, and received their 2011 Distinguished Scientific Contribution Award. Brandi C. Fink, Assistant Professor, University of New Mexico Department of Psychiatry and Behavioral Sciences. Dr. Fink is a licensed clinical psychologist studying neuropsychophysiological mediators of the association between alcohol use and intimate partner violence. The goals of this work are to identify mechanisms that may amenable as adjunctive treatments to a novel behavioral treatment for alcohol-related intimate partner violence. Teresa Leyro, PhD is an Assistant Professor in the Department of Psychology at Rutgers, The State University of New Jersey, and the Director of the Affective and Biological Underpinnings of Substance Use and Anxiety (ABUSA) Laboratory. Her research program employs a multi-method approach toward identifying underlying cognitive-affective and biological risks for co-occurring emotional symptomatology and health risk behaviors, with a focus on nicotine dependence. Currently, she is examining sympathetic-adrenal-medullary and parasympathetic nervous systems as well as hypothalamic-pituitary-adrenal axis activity in response to stress and nicotine withdrawal to better understand cessation processes.

Learning Objectives. Following this presentation, participants will be able to:

1. Discuss evidence suggesting HRV can be used as an index of behavioral inhibition
2. Describe to learners two integrated ways autonomic dysregulation may promote smoking maintenance in anxious smokers: (a) by affecting cognitive regulatory processes; and (b) by affecting physiological regulatory systems.
3. Define how the heart and brain communicate with one another to impact behavior.

8. Trauma, PTSD and Substance Use: Epidemiology, Special Populations and a Systematic Review

Abstract. We will present findings from research relating substance use/substance use disorders to trauma, PTSD and other co-morbid psychiatric conditions. Notably, each presentation in this symposium utilized very different methodological approaches. After a brief introduction from Dr. Leeman, Dr. Beseler will present findings from secondary analyses of the NESARC Waves 1 and 2 comparing and contrasting cannabis and other drug users, with and without substance use disorder, in relation to PTSD, depression, anxiety, suicidality and various medical conditions. Dr. Lansing will then report results from research modifying an existing self-report measure of disinhibiting effects of alcohol, including efforts to incorporate disinhibiting effects related to PTSD symptomatology and other substance use among adolescents who are high-risk with histories of polysubstance use, delinquency and significant trauma. Ms. Frohe will follow with a report from a systematic review of the literature concerning substance-related information from the randomized controlled trial literature testing treatments for PTSD. Dr. Trim will close as Discussant with a summary and interpretation of the findings from these related yet unique presentations with a specific focus on public health implications. The topic of this symposium is pertinent to clinicians and professionals in the areas of epidemiology and public health with interests in comorbidity among substance use, psychiatric and medical conditions.

Presenters. Robert Leeman, Ph.D.; Cheryl Beseler, Ph.D, Amy Lansing, Ph.D., Tessa Frohe, B.A.; Ryan Trim, Ph.D.

Presenter Qualifications. Robert Leeman, Ph.D., Associate Professor, Department of Health Education & Behavior, University of Florida and Adjunct Assistant Professor, Department of Psychiatry, Yale School of Medicine. Dr. Leeman's primary research focus concerns difficulties with self-control and alcohol use. He has expertise in human laboratory methods, randomized controlled trial and survey research. Dr. Leeman has received funding from NIH and ABMRF/the Foundation for Alcohol Research. Cheryl Beseler, Ph.D., Affiliate faculty member and researcher in the Psychology Department at Colorado State University and statistician at the University of Colorado Medical School. Cheryl Beseler completed a Ph.D. in Epidemiology at Colorado State University in 2005. Dr. Beseler's work has focused on the dimensionality of alcohol and marijuana in support of changes to the DSM-5, the genetics of substance use and co-morbid disorders. She has been funded by the State of Colorado for the past three years to study the effects

of the legalization of recreational marijuana use on youth across the State of Colorado. Amy Lansing, Ph.D., Assistant Professor and Director of Cognitive and Neurobehavioral Studies in Aggression, Coping, Trauma and Stress, Department of Psychiatry University of California-San Diego and Adjunct Professor, Department of Sociology, Division of Criminology, San Diego State University. Dr. Amy Lansing holds a Doctorate in Clinical Psychology, with specializations in Neuropsychology, Developmental Trauma and Forensic Epidemiology; has a judicial appointment to the San Diego County Juvenile Justice Commission and is an independent contractor for the State of California, providing assessments of mentally disordered adult offenders. Her research program is dedicated to understanding the neurobehavioral underpinnings of high-risk behaviors and functional impairment in underserved and vulnerable populations, such as juvenile delinquents and maltreated youth. Support for her research comes from the National Institute of Child and Human Development and the National Institute on Minority Health and Health Disparities. Tessa Frohe, B.A., Doctoral Student and Graduate Research Assistant, Department of Health Education, University of Florida. Ms. Frohe has studied addictive behaviors for the past four years, beginning with undergraduate training in the basics of addictions counseling. Her interests include comorbidities between addictive behaviors and conditions such as depression and anxiety and mindfulness-based relapse prevention. Ryan Trim, Ph.D., Associate Professor, Department of Psychiatry, University of California-San Diego. Dr. Trim graduated with a Ph.D. in clinical psychology from Arizona State University after completing an APA-approved internship at UCSD/VA San Diego. Dr. Trim serves as the Director of the Substance Abuse/Mental Illness Clinic at the VA San Diego. His research focuses on the impact of individual and environmental risk factors on substance use and related high-risk behaviors across the lifespan. He has served as a PI or key contributor for grants funded by NIH, VA, DoD, and ABMRF.

Learning Objectives. Following this presentation, participants will be able to:

1. Compare and contrast co-morbid conditions suffered by cannabis and opioid users and discuss their public health impact
2. Describe substance-related disinhibition in high-risk, trauma-exposed adolescents compared to normative adolescents
3. Summarize current knowledge on relationships between PTSD and substance use from the randomized controlled trial literature

9. A Behavioral Economic Perspective on Persistent Tobacco Use in People With Psychopathology

Abstract. Cigarette smoking rates are decreasing in the general population, but are stable among people with psychiatric disorders. Most people with psychiatric disorders are motivated to quit but are more likely to relapse during cessation attempts. This symposium will explore how a behavioral economics perspective can inform our understanding of mechanisms and potential treatments for tobacco dependence in people with psychiatric disorders, with applications to other drug comorbidities. Dr. Tidey will discuss her laboratory research

indicating that smokers with schizophrenia overvalue cigarette reinforcement relative to reinforcement from alternative sources, and will describe how tobacco regulatory policies could reduce tobacco use among people with serious mental illness. Dr. Audrain-McGovern will discuss her laboratory and longitudinal research that links overvaluation of cigarette reinforcement to smoking persistence among depression-prone smokers, and will describe how a novel behavioral economic/behavioral activation treatment may promote smoking cessation while preventing post-cessation weight gain. Dr. Leventhal will discuss his research indicating that anhedonia and other transdiagnostic factors contribute to the comorbidity between psychiatric disorders and tobacco dependence by amplifying the positive and negative reinforcing effects of smoking. Dr. Murphy will synthesize these findings and lead a discussion of implications for policy, cessation, and connections to other drug comorbidities.

Presenters. Jennifer W. Tidey, Ph.D. Janet Audrain-McGovern, Ph.D., Adam Leventhal, Ph.D., James Murphy, Ph.D.

Presenter Qualifications. Dr. Tidey is a Professor of Psychiatry and Human Behavior and Director of the Addictive Behaviors Research Laboratory in the Center for Alcohol and Addiction Studies at Brown University. For the past 20 years, Dr. Tidey has led NIH-funded research aimed at identifying biological and environmental mechanisms underlying the high rates of cigarette smoking in people with serious mental illness and developing effective treatments and regulatory approaches to reduce smoking in these patients. Dr. Audrain-McGovern is an Associate Professor in the Department of Psychiatry at the Perelman School of Medicine and a member of the Abramson Cancer Center at the University of Pennsylvania. Over the past 20 years, she has led laboratory studies, randomized clinical trials, and longitudinal cohort studies aimed at understanding mechanisms that contribute to tobacco use in adult and adolescent populations. Dr. Leventhal is an Associate Professor of Preventive Medicine and Psychology at the University of Southern California Keck School of Medicine and the USC Norris Comprehensive Cancer Center. He is an addiction psychologist with expertise in the epidemiology and psychopharmacology of tobacco use and other addictive or health-damaging behaviors. He is Director of the USC Health, Emotion, & Addiction Laboratory, which conducts interdisciplinary research on the intersection between addiction, mental health, and health behavior. Dr. Murphy is a Professor of Psychology and Director of Clinical Training at the University of Memphis, where he directs the Health Addiction and Behavioral Intervention Team (HABIT). His research focuses on identifying behavioral economic and decision making processes related to addictive behaviors, and using this information to design novel interventions for treating addictive disorders.

Learning Objectives. Following this presentation, participants will be able to:

1. Explain a behavioral economics view of the comorbidity between psychiatric illnesses and tobacco.
2. Describe how this perspective informs testing tobacco treatments and regulatory approaches.
3. Discuss how this perspective may be applied to understanding other psychiatric-drug comorbidity.

CONTINUING EDUCATION GRIEVANCE PROCEDURE

The Society of Addiction Psychology (APA Division 50) and the Collaborative Perspectives on Addiction meeting are fully committed to conducting all activities in strict conformance with the American Psychological Association's Ethical Principles of Psychologists. The Society of Addiction Psychology (APA Division 50) and the Collaborative Perspectives on Addiction meeting will comply with all legal and ethical responsibilities to be non-discriminatory in promotional activities, program content and in the treatment of program participants. (American Psychological Association Education Directorate Continuing Education Grievance Procedure). The CE Chair (Cynthia Glidden-Tracey, PhD) in consultation with the 2017 Collaborative Perspectives on Addiction Meeting Co-Chairs, Robert Leeman, PhD, and James Murphy, PhD, will be responsible for monitoring and assessing compliance with APA standards.

While the Society of Addiction Psychology (APA Division 50) and the Collaborative Perspectives on Addiction meeting go to great lengths to assure fair treatment for all participants and attempts to anticipate problems, there will be occasional issues which come to the attention of the convention staff which require intervention and/or action on the part of the convention staff or continuing education committee. (American Psychological Association Education Directorate Continuing Education Grievance Procedure)

The guidelines for handling grievances are described below:

Participants should file grievances in written form for record keeping purposes. You do not need to sign the grievance.

Depending on the grievance, the following actions will be taken:

1. If your grievance concerns a speaker, the content presented by a speaker, or the style of presentation, please put your comments in written format. The CE Chair (Cynthia Glidden-Tracey, PhD) will keep your identity confidential and convey your comments to the speaker.
2. If your grievance concerns a specific CPA 2017 CE program, its content, level of presentation or the facilities in which the CE offering was conducted, please submit your grievance for review by the CE Chair Cynthia Glidden-Tracey, PhD via email at cglidden@asu.edu and CPA 2017 Program Co-Chairs Robert Leeman, PhD, via email at robert.leeman@ufl.edu or phone at (352) 294-1808, and James Murphy, PhD, via email at jgmurphy@memphis.edu or phone at (901) 678-2630.
3. If you request action, CPA 2017 Program Co-Chairs Robert Leeman, PhD, and James Murphy, PhD (robert.leeman@ufl.edu, jgmurphy@memphis.edu, in consultation with the CE Chair Cynthia Glidden-Tracey, (cglidden@asu.edu) will:
 - a. attempt to remedy the situation or
 - b. provide a partial or full refund of the CE fee.
4. If your grievance concerns the CE staff, the CE Chair will attempt to arbitrate.

SCHEDULE AT A GLANCE

Friday			
Barcelona Ballroom			
March 24	Barcelona	Majorca	Catalina
9:00 AM	Opening of the Meeting		
9:15 AM	Keynote Address: Dr. William Miller Motivational Interviewing at the Crossroads 1 CE		
10:15 AM	Break (Mezzanine)		
10:30 AM	Obesity and Substance Use: A Complex Relationship 1.25 CEs	The Pains of Chronic Pain and Opioid Use	Clinical Workshop: Emotion Regulation Training for Alcohol Use Disorder: Helping Clients Manage Negative Emotions 2 CEs
11:45 AM	Poster session 1 (Casablanca)		
12:30 PM	Ticketed Lunch or Lunch on Your Own		
1:45 PM	Emotion Dysregulation in Substance Use and Substance Use Disorders 1.25 CEs	A Demonstration of Feasibility and Utility of Multi-Site Collaborations in College Student Substance Use	Clinical workshop: Cognitive-Behavioral Therapy (CBT) for Alcohol and Drug Problems 2.75 CEs
3:00 PM	Break (Mezzanine)		
3:15 PM	Comorbid Substance Use and Mental Health Conditions: Implications for Prevention and Treatment 1.25 CEs	Impulsivity and Substance Use: Novel and Innovative Methodological Approaches	
4:30PM	Break (Mezzanine)		
4:45 PM	Early Career Showcase	Person-Centered Approaches to Exploring Heterogeneity in Substance Use and Treatment Responses	Clinical Workshop: Treating Suicidal Thoughts and Behaviors in Adults with SUDs 1.25 CEs
6:00PM	Poster Session 2 & Social Hour (Casablanca)		
Saturday			
Barcelona Ballroom			
March 25	Barcelona	Majorca	Catalina
8:00 AM	Poster Session 3 & Continental Breakfast (Casablanca)		
9:00 AM	Addressing the Needs of Pregnant Women in Substance Use Treatment 1.25 CEs	Emotion Regulation Difficulties as a Concomitant Substance Use Problem 1.25 CEs	Clinical Workshop: SBIRT Basics: Development and Application of SBIRT Skills in Diverse Settings 2.75 CEs
10:15 AM	Break (Mezzanine)		
10:30 AM	The "Future's so Bright"? Trends in Technology-Enhanced Addiction Recovery Management 1.25 CEs	Clinical Implications of Research on Protective Behavioral Strategies for Alcohol, Marijuana	
11:45 AM	Poster Session 4 (Casablanca)		
12:30 PM	Networking Lunch (Mezzanine)		
1:45 PM	Keynote Address: Dr. Kathleen Grant Brain Imaging, Temperament and Cognitive Function in a Monkey Model or Chronic Alcohol Self-Administration 1 CE		
2:45 PM	Break (Mezzanine)		
3:00 PM	Heart Rate Variability as a Dynamic, Real-Time Indicator of Active Brain and Behavior Mechanisms 1.25 CEs	Trauma, PTSD and Substance Use: Epidemiology, Special Populations and a Systematic Review 1.25 CEs	Clinical Workshop: Drug Use, Misuse, and Abuse: Recent Advances in Psychopharmacology 2.75 CEs
4:15 PM	Break (Mezzanine)		
4:30 PM	A Behavioral Economic Perspective on Persistent Tobacco Use in People with Psychopathology, then Awards Ceremony 1.25 CEs		
5:45 PM	Awards Ceremony (Barcelona)		
6:00 PM	Poster Session 5 & Social Hour (Casablanca)		